trending Market Intelligence /marketintelligence/en/news-insights/trending/YX8uSZpRRJrq0iEe-2uCug2 content esgSubNav
In This List

Takeda takes equity stake in newly launched Izana Bioscience

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Takeda takes equity stake in newly launched Izana Bioscience

Takeda Pharmaceutical Co. Ltd. acquired a strategic equity stake in newly launched Izana Bioscience, as part of a licensing agreement.

Izana is a clinical-stage translational medicine company initially focused on ankylosing spondylitis, a type of arthritis that affects the spine.

Under the deal, financial terms of which were not disclosed, Japan-based Takeda granted U.K.-based Izana a licence to develop, manufacture and commercialize namilumab worldwide and for any indication.

Takeda has rights to sublicense namilumab under a licence agreement with Amgen Inc.

Namilumab, or IZN-101, is an antibody that has shown effectiveness in a phase 2 proof-of-concept trial conducted in over 100 rheumatoid arthritis patients.